Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lineage Commitment01:21

Lineage Commitment

3.6K
Commitment is the  process whereby stem cells:
3.6K
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

3.5K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.5K
Mismatch Repair01:20

Mismatch Repair

5.6K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
5.6K
Hematopoiesis01:21

Hematopoiesis

7.4K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
7.4K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.6K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.6K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

601
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
601

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Germline cancer risk alleles drive myelodysplastic neoplasms throughout adulthood.

Leukemia·2026
Same author

Prognostic impact of somatic mutations among patients with pleural and peritoneal mesothelioma.

NPJ precision oncology·2026
Same author

Functional analysis of germline RUNX1 variants identified in individuals with suspected familial platelet disorder.

Blood advances·2026
Same author

Focusing a sPOTlight on POT1.

Blood·2026
Same author

Update of germ line RUNX1 variant curation rules: version 3.1.

Blood advances·2026
Same author

Correspondence on "ACMG SF v3.3 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG)" by Lee et al.

Genetics in medicine : official journal of the American College of Medical Genetics·2026

Related Experiment Video

Updated: Nov 2, 2025

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

4.2K

Germline predisposition to hematopoietic malignancies.

Simone Feurstein1, Michael Drazer1,2, Lucy A Godley1,2

  • 1Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA.

Human Molecular Genetics
|June 8, 2021
PubMed
Summary

Germline predisposition disorders increasing the risk of hematopoietic malignancies (HMs) are more common than previously believed. Genetic testing impacts patient care and requires standardized platforms and improved genetic counseling for better outcomes.

More Related Videos

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells
11:06

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells

Published on: February 24, 2014

13.2K
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.9K

Related Experiment Videos

Last Updated: Nov 2, 2025

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

4.2K
Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells
11:06

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells

Published on: February 24, 2014

13.2K
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.9K

Area of Science:

  • Hematology
  • Genetics
  • Oncology

Background:

  • Germline predisposition disorders conferring risk for hematopoietic malignancies (HMs) are now recognized as more common than previously understood.
  • The identification of germline susceptibility risk alleles significantly influences clinical management and surveillance for affected individuals and their relatives.

Purpose of the Study:

  • To highlight the increasing prevalence and clinical significance of germline predisposition disorders in hematopoietic malignancies.
  • To identify current challenges and knowledge gaps in the diagnosis, management, and genetic counseling of these conditions.
  • To propose future directions for comprehensive genetic testing and preventive strategies.

Main Methods:

  • Review of current literature and clinical practices regarding germline predisposition disorders and HMs.
  • Analysis of challenges in clinical testing, including provider familiarity, sample quality, and platform standardization.
  • Identification of knowledge gaps concerning predisposition genes, transplant permissibility, and genetic counseling delivery.

Main Results:

  • Next-generation sequencing has revealed a wide spectrum of germline disorders predisposing to HMs.
  • Clinical testing faces hurdles such as healthcare provider unfamiliarity, sample integrity issues, and lack of standardized gene panels.
  • Significant knowledge gaps persist regarding the full spectrum of predisposition genes and optimal management strategies.

Conclusions:

  • Germline genetic testing is crucial for managing patients with HMs and their families.
  • Standardization of testing platforms, improved genetic counseling, and development of preventive strategies are needed.
  • Future implementation of comprehensive germline testing for patients and donors may improve health outcomes.